- Home
- CENN vs FGEN Comparison
CENN vs FGEN Comparison
Compare CENN & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CENN
- FGEN
- Stock Information
- Founded
- CENN 2013
- FGEN 1993
- Country
- CENN United States
- FGEN United States
- Employees
- CENN N/A
- FGEN N/A
- Industry
- CENN Auto Manufacturing
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CENN Consumer Discretionary
- FGEN Health Care
- Exchange
- CENN Nasdaq
- FGEN Nasdaq
- Market Cap
- CENN 28.3M
- FGEN 33.5M
- IPO Year
- CENN N/A
- FGEN 2014
- Fundamental
- Price
- CENN $0.83
- FGEN $0.31
- Analyst Decision
- CENN
- FGEN Strong Buy
- Analyst Count
- CENN 0
- FGEN 1
- Target Price
- CENN N/A
- FGEN $10.00
- AVG Volume (30 Days)
- CENN 142.4K
- FGEN 1.6M
- Earning Date
- CENN 05-11-2025
- FGEN 05-05-2025
- Dividend Yield
- CENN N/A
- FGEN N/A
- EPS Growth
- CENN N/A
- FGEN N/A
- EPS
- CENN N/A
- FGEN N/A
- Revenue
- CENN $31,297,393.00
- FGEN $29,621,000.00
- Revenue This Year
- CENN N/A
- FGEN $544.98
- Revenue Next Year
- CENN N/A
- FGEN $9.45
- P/E Ratio
- CENN N/A
- FGEN N/A
- Revenue Growth
- CENN 142.48
- FGEN N/A
- 52 Week Low
- CENN $0.64
- FGEN $0.18
- 52 Week High
- CENN $2.30
- FGEN $2.15
- Technical
- Relative Strength Index (RSI)
- CENN 40.85
- FGEN 38.31
- Support Level
- CENN $0.86
- FGEN $0.28
- Resistance Level
- CENN $0.98
- FGEN $0.33
- Average True Range (ATR)
- CENN 0.07
- FGEN 0.04
- MACD
- CENN -0.01
- FGEN -0.00
- Stochastic Oscillator
- CENN 4.53
- FGEN 14.16
About CENN Cenntro Electric Group Limited
Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles. Its vehicles include Metro, Logistar 400, Logistar 200, Neibor 200, and ORV. The company's geographical segments include Europe, America, and Asia.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.